Rituximab Maintenance Delays Need for More Aggressive Treatment in Follicular Lymphoma

Researchers sponsored in part by Cancer Research UK explored whether patients with advanced-stage, low tumor burden follicular lymphoma could benefit from rituximab.

Rituximab has the potential to delay the need for chemotherapy or radiotherapy in a more proactive manner as compared to the current protocol of watchful waiting. They also explored whether this strategy had an effect on quality of life.

The study recruited 379 patients from 118 centers in the U.K., Australia, New Zealand, Turkey, and Poland. They were randomly assigned either to watchful waiting or maintenance rituximab.

Initially, 84 patients were recruited to rituximab induction, in which they received rituximsb once a week for four weeks but the arm was closed early.

Investigators found a significant difference in the time to start of new treatment at three years:

  • 46 percent of patients in the watchful waiting group did not need treatment at three years
  • 88 percent in the maintenance rituximab group did not need treatment at three years
  • 78 percent in the rituximab induction group did not need treatment at three years

Rituximab should be considered as a treatment option

Compared with the watchful waiting group, patients in the maintenance rituximab group had significant improvements in the Mental Adjustment to Cancer scale score, and Illness Coping Style score between baseline and month 7. Patients in the rituximab induction group did not show improvements in their quality of life compared with the watchful waiting group.

There were 18 serious adverse events reported in the rituximab groups (four in the rituximab induction group and 14 in the maintenance rituximab group), 12 of which were grade 3 or 4 (five infections, three allergic reactions, and four cases of neutropenia), all of which fully resolved.

Researchers concluded that rituximab monotherapy should be considered as a treatment option for patients with asymptomatic, advanced-stage, low tumor burden follicular lymphoma.

Source: The Lancet

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap